Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia

Figure 1

CD56 overexpression in de novo non-M3 AML patients. (a, b) Flow cytometry plots of the CD56 expression in de novo non-M3 AML, ALL, and healthy (normal) patients before treatment. Scatter plot showing a higher intensity of the CD56 expression in de novo non-M3 AML compared with ALL () and normal controls (). (c, d) Markedly decreased the CD56 expression in de novo non-M3 AML patients after the first induction treatment (1 cycle) (). (e, f) After remission (CR), CD56 still remained in the very low expression level ().

(a)

(b)

(c)

(d)

(e)

(f)